Peimine inhibits variants of SARS‐CoV‐2 cell entry via blocking the interaction between viral spike protein and ACE2

Coronavirus disease 2019 (COVID‐19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Several vaccines against SARS‐CoV‐2 have been approved; however, variants of concern (VOCs) can evade vaccine protection. Therefore, developing small compound drugs that directly...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of food biochemistry 2022-10, Vol.46 (10), p.e14354-n/a
Hauptverfasser:	Wang, Wei‐Jan, Chen, Yeh, Su, Wen‐Chi, Liu, Yen‐Yi, Shen, Wan‐Jou, Chang, Wei‐Chao, Huang, Sheng‐Teng, Lin, Cheng‐Wen, Wang, Yu‐Chuan, Yang, Chia‐Shin, Hou, Mei‐Hui, Chou, Yu‐Chi, Wu, Yang‐Chang, Wang, Shao‐Chun, Hung, Mien‐Chie
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE2 Angiotensin-Converting Enzyme 2 - genetics Binding Sites Cevanes COVID-19 Drug Treatment COVID-19 Vaccines Fritillaria Glycoproteins Humans Molecular Docking Simulation Original peimine Peptidyl-Dipeptidase A - chemistry Protein Binding SARS-CoV-2 Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - genetics variants of concern Viral Proteins - metabolism Virus Internalization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!